• Publications
  • Influence
Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease.
Increasing recognition that Parkinson's disease (PD) may start outside of the substantia nigra has led to a rapidly expanding effort to define prodromal stages of PD, before motor signs permitExpand
  • 338
  • 14
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid
In multiple sclerosis, brain-reactive T cells invade the central nervous system (CNS) and induce a self-destructive inflammatory process. T-cell infiltrates are not only found within the parenchymaExpand
  • 131
  • 12
Stroke-Induced Immunodepression: Experimental Evidence and Clinical Relevance
Stroke affects the normally well-balanced interplay of the 2 supersystems: the nervous and the immune system. Recent research elucidated some of the involved signals and mechanisms and, importantly,Expand
  • 339
  • 10
Cardiovascular autonomic dysfunction in Parkinson's disease
Symptoms of cardiovascular dysautonomia are a common occurrence in Parkinson's disease (PD). In addition to this dysautonomia as part of PD itself, dysfunction of the autonomic nervous system (ANS)Expand
  • 116
  • 9
Multiple sclerosis beyond EDSS: depression and fatigue
  • T. Ziemssen
  • Medicine
  • Journal of the Neurological Sciences
  • 1 February 2009
Depression and fatigue are common symptoms of multiple sclerosis and are the primary determinants of impaired quality of life in this demyelinating neurological disease. The twelve-month prevalenceExpand
  • 136
  • 8
Acute Cerebrovascular Disease in the Young: The Stroke in Young Fabry Patients Study
Background and Purpose— Strokes have especially devastating implications if they occur early in life; however, only limited information exists on the characteristics of acute cerebrovascular diseaseExpand
  • 136
  • 6
Glatiramer acetate: mechanisms of action in multiple sclerosis.
Glatiramer acetate (GA), formerly known as copolymer 1, is a mixture of synthetic polypeptides composed of four amino acids resembling the myelin basic protein (MSP). GA has been shown to be highlyExpand
  • 155
  • 5
Optimizing treatment success in multiple sclerosis
Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the introduction of several disease-modifying therapies (DMTs), the burden of progressive disability andExpand
  • 95
  • 5
Therapeutic decisions in multiple sclerosis: moving beyond efficacy.
Several innovative disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been licensed recently or are in late-stage development. The molecular targets of several ofExpand
  • 74
  • 5